Madrigal Pharmaceuticals Q1 2024 GAAP EPS $(7.38) Misses $(6.17) Estimate
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals reported a Q1 2024 GAAP EPS loss of $(7.38), missing the consensus estimate of $(6.17) by 19.61%.
May 07, 2024 | 11:21 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Madrigal Pharmaceuticals reported a larger than expected Q1 2024 loss per share of $(7.38), missing the consensus estimate of $(6.17).
The significant miss in earnings expectations typically leads to negative investor sentiment in the short term, potentially causing a decrease in stock price as the market adjusts to the new information.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100